drugset / Trial / NCT00160446

A Study to Evaluate the Safety and Effectiveness of Three Asoprisnil Doses in the Treatment of Women With Endometriosis

NCT00160446

Phase 2 Completed 130 enrolled Abbott
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this study is to determine the safety and effectiveness of three doses of asoprisnil, compared to placebo, in the treatment of women with endometriosis.

Timeline

Start
2000-05
Primary completion
2001-07
Completion
2001-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Asoprisnil Other / unclassified 5 mg Oral
Subject Asoprisnil Other / unclassified 10 mg Oral
Subject Asoprisnil Other / unclassified 25 mg Oral

Indications